Contrasting Shoulder Innovations (NYSE:SI) & PROCEPT BioRobotics (NASDAQ:PRCT)

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) and Shoulder Innovations (NYSE:SI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 4.0% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares PROCEPT BioRobotics and Shoulder Innovations”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PROCEPT BioRobotics $308.05 million 4.61 -$95.57 million ($2.02) -12.23
Shoulder Innovations $47.32 million 8.89 -$40.36 million ($1.62) -12.41

Shoulder Innovations has lower revenue, but higher earnings than PROCEPT BioRobotics. Shoulder Innovations is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

PROCEPT BioRobotics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Shoulder Innovations has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500.

Profitability

This table compares PROCEPT BioRobotics and Shoulder Innovations’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics -32.60% -33.23% -23.58%
Shoulder Innovations -51.72% -25.37% -20.87%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for PROCEPT BioRobotics and Shoulder Innovations, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics 2 9 2 3 2.38
Shoulder Innovations 1 0 5 0 2.67

PROCEPT BioRobotics currently has a consensus price target of $25.25, suggesting a potential upside of 2.23%. Shoulder Innovations has a consensus price target of $25.75, suggesting a potential upside of 28.11%. Given Shoulder Innovations’ stronger consensus rating and higher probable upside, analysts clearly believe Shoulder Innovations is more favorable than PROCEPT BioRobotics.

Summary

Shoulder Innovations beats PROCEPT BioRobotics on 9 of the 14 factors compared between the two stocks.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics develops and commercializes surgical robotic systems for urology, with a focus on treating benign prostatic hyperplasia, or BPH, an enlargement of the prostate that can cause urinary symptoms. The company’s core offering is Aquablation therapy, delivered using its AquaBeam Robotic System. The procedure combines imaging guidance with a surgeon-controlled, robotically assisted waterjet to remove prostate tissue. PROCEPT also offers its HYDROS Robotic System, a platform designed to deliver Aquablation therapy.

About Shoulder Innovations

(Get Free Report)

Shoulder Innovations, Inc. is a medical technology company focused on developing and commercializing products for shoulder replacement surgery. Its offerings are designed for orthopedic surgeons treating patients with shoulder conditions that may require joint replacement. The company’s product portfolio includes shoulder implant systems such as its InSet glenoid and Catalyst reverse shoulder technologies, along with related surgical instruments. These products support different approaches to shoulder arthroplasty, including procedures that replace or reconstruct parts of the shoulder joint.

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.